You are here

Oligonucleotide Inhibitors of DNA Methyltransferases

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43GM109507-01
Agency Tracking Number: R43GM109507
Amount: $201,941.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIGMS
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
17736-15TH AVE NW
SHORELINE, WA 98177-3303
United States
DUNS: 967346805
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ANDREW SLEDZIEWSKI
 (206) 228-3487
 azs@metheorx.com
Business Contact
 ANDREW SLEDXIEWSKI
Phone: (206) 228-3487
Email: azs@metheorx.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): In this Phase I project Metheor Therapeutics is proposing a unique approach to developing novel DNA methyltransferase (DNMT) inhibitors, testing the concept of a substrate trap designed to capture and deplete the enzyme. Inhibition of DNMT activity is a validated therapeutic approach for Myelodysplastic Syndrome and Acute Myeloid Leukemia. Two nucleoside analogs, Vidaza and Dacogen are marketed for these indications but dose-limiting toxicities due to incorporation in the genome limit their applicationin these indications as well as for other cancers or diseases. The development of novel inhibitors that function without incorporation in the genome has the potential to significantly broaden the clinical use of DNMT inhibitors. In our approach, we merged advances in oligonucleotide chemistry driven by the development of therapeutic RNAi compounds, with the growing understanding of DNMT interaction with oligonucleotide substrates to produce DNMT Trapping Oligonucleotides

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government